Analytical Data
-
基因名
HLA-E*01:03&B2M&CMV UL40(VMAPRTVLL) Monomer
- Application
-
别名
HLA-E*0103 & B2M & CMV UL40 (VMAPRTVLL)
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P13747 (G22-I305)&P61769
-
表达区间
P13747 (G22-I305)&P61769 (I21-M119)&VMAPRTVLL
-
分子量
40-43 kDa and 12 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HLA-E is a non-classical class I major histocompatibility complex (MHC) molecule that plays a crucial role in immune regulation and recognition of stressed or infected cells. It presents peptide antigens, particularly those derived from the leader sequences of MHC class I molecules, to immune cells such as CD94/NKG2A-expressing natural killer (NK) cells. The HLA-E*01:03 variant, in conjunction with beta-2-microglobulin (B2M), enhances the stability and surface expression of HLA-E. The cytomegalovirus (CMV) UL40-derived peptide (VMAPRTVLL) is a well-documented ligand for HLA-E, allowing CMV to escape immune surveillance by employing this pathway. The study of HLA-E*01:03 in complex with B2M and the UL40 peptide aims to elucidate the molecular mechanisms behind viral evasion strategies and to assess the potential of HLA-E as a therapeutic target. By generating a recombinant monomeric protein of HLA-E*01:03/B2M/CMV UL40, researchers can investigate its structural characteristics and how peptide binding influences the interaction with NK cells. Understanding this interaction is vital for developing immune-based therapies against viral infections and for enhancing vaccine effectiveness, particularly in individuals with compromised immune systems.
